Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients
The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.
Checked against the public recordLast updated Apr 3, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Dana-Farber Cancer Institute
- Interventions being studied
- Drug: OSI-774 (Tarceva)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age: 70 years of age or older * Stage IV or IIIB non-small cell lung cancer (NSCLC) * Measurable tumor(s) * Three or more weeks since prior radiation therapy * Three or more weeks since prior major surgery * Must at least be able to walk and capable of taking care of oneself although unable to carry out work activities. * Must be up and about more than 50% of waking hours. * Life expectancy of 8 weeks or more * Blood tests that show kidneys, liver and bone marrow to be working adequately * Completely healed from previous oncologic or other major surgery Exclusion Criteria: * Prior chemotherapy regimen for non-small cell lung cancer * Prior exposure to OSI-774 or similar treatments such as trastuzumab, ZD1839, C225, etc. * Uncontrolled central nervous system metastases * Concurrent active cancer * Malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin * Prior chemotherapy for any malignant disease * Difficulty swallowing * A disease or disorder that interferes with ability to digest and absorb food * A medical condition that could make it unsafe for patient to participate in this study
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Massachusetts General HospitalBoston, Massachusetts
- Dana-Farber Cancer InstituteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 3, 2020. Always confirm current availability with the study team.